Today, ACIP voted unanimously (10 YES – 0 NO for all votes) to recommend nirsevimab for use in infants <8 months born or entering their first RSV season, and for children aged 8-19 months who are at increased risk of RSV disease entering their second RSV season (agenda and slides). The Committee also voted for the inclusion of nirsevimab in VFC:
- Infants aged <8 months born during or entering their first RSV reason are recommended to receive one dose of nirsevimab (50 mg for infants <5 kg and 100 mg for infants ≥5kg)
- Children aged 8-19 months who are at increased risk of severe RSV disease and entering their second RSV season are recommended to receive one dose of nirsevimab (200 mg)
- Approve the Vaccines for Children (VFC) resolution for nirsevimab for RSV.
The Committee heard the Evidence to Recommendations (EtR) framework, as well as a presentation from ISD Director Dr. Georgina Peacock on implementation considerations and challenges. AIM also gave an oral public comment highlighting the results from our nirsevimab implementation survey conducted with program managers at the end of July, and the need for continued collaboration with CDC/planning assumptions to maximize the impact of this life saving treatment.